Lexeo Therapeutics Files Q1 2025 10-Q
Ticker: LXEO · Form: 10-Q · Filed: May 12, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotech
TL;DR
Lexeo Therapeutics filed its Q1 2025 10-Q. Key dates and agreements noted.
AI Summary
Lexeo Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's business address is 345 Park Avenue South, Floor 6, New York, NY 10010. Key dates mentioned include the IPO on November 7, 2023, and various license agreements with Cornell University and UCSD dating back to 2020 and 2021.
Why It Matters
This filing provides an update on Lexeo Therapeutics' financial and operational status for the first quarter of 2025, which is crucial for investors to assess the company's progress and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Lexeo Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market acceptance.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2025-05-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2023-11-07 — IPO Date (Marks the company's initial public offering.)
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Filer of the 10-Q report
- 345 Park Avenue South, Floor 6, New York, NY 10010 (company) — Business and mailing address
- 2025-03-31 (date) — Conformed period of report
- 2025-05-12 (date) — Filed as of date
- 2023-11-07 (date) — Date of IPO
- Cornell University (company) — Party to license agreements
- UCSD (company) — Party to license agreements
FAQ
What is the reporting period for this 10-Q filing?
The conformed period of report is 20250331, meaning the filing covers the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed as of May 12, 2025.
What is Lexeo Therapeutics' business address?
Lexeo Therapeutics' business address is 345 Park Avenue South, Floor 6, New York, NY 10010.
What are some key dates related to Lexeo Therapeutics' agreements mentioned in the filing?
The filing mentions license agreements with Cornell University dating back to November 1, 2020, and with UCSD dating back to April 23, 2020, and October 4, 2021.
When did Lexeo Therapeutics have its Initial Public Offering (IPO)?
Lexeo Therapeutics had its IPO on November 7, 2023.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).